NANOPHASE TECHNOLOGIES Corp (NASDAQ:SLSN - Get Free Report) COO Kevin Cureton sold 4,693 shares of NANOPHASE TECHNOLOGIES stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $3.96, for a total transaction of $18,584.28. Following the completion of the transaction, the chief operating officer now owns 192,212 shares of the company's stock, valued at $761,159.52. The trade was a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kevin Cureton also recently made the following trade(s):
- On Friday, June 6th, Kevin Cureton sold 38,807 shares of NANOPHASE TECHNOLOGIES stock. The stock was sold at an average price of $3.80, for a total transaction of $147,466.60.
NANOPHASE TECHNOLOGIES Stock Performance
Shares of SLSN traded up $0.15 during mid-day trading on Monday, reaching $3.99. The company's stock had a trading volume of 123,322 shares, compared to its average volume of 91,884. The firm has a market cap of $279.71 million, a price-to-earnings ratio of 99.75 and a beta of 0.76. NANOPHASE TECHNOLOGIES Corp has a 52 week low of $1.21 and a 52 week high of $16.56.
Analyst Ratings Changes
Separately, Wall Street Zen raised shares of NANOPHASE TECHNOLOGIES to a "hold" rating in a research note on Thursday, May 22nd.
View Our Latest Stock Analysis on SLSN
NANOPHASE TECHNOLOGIES Company Profile
(
Get Free Report)
Nanophase Technologies Corporation provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in the United States. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics, sun care, and skin care under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications.
Further Reading
Before you consider Solesence, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solesence wasn't on the list.
While Solesence currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
